Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters











Database
Publication year range
1.
Dev Biol Stand ; 50: 249-59, 1981.
Article in English | MEDLINE | ID: mdl-6281108

ABSTRACT

In 1974 a new industrial technique for concentration and purification of FMD virus was presented at the OIE Conference. The bulk inactivated virus from this technique was stored in liquid nitrogen vapour until required for vaccine formulation. In 1981, having applied this technique regularly for seven years, we now describe the results obtained and the advantages gained in the field of trivalent O, A, C bovine vaccine production. Vaccines prepared from such bulk virus stocks after several years storage give good protection against virulent virus challenge.


Subject(s)
Aphthovirus/physiology , Vaccines/standards , Animals , Antigens, Viral/isolation & purification , Aphthovirus/isolation & purification , Cattle , Cell Line , Cricetinae , Drug Stability , Freezing , Kidney , Nitrogen , Quality Control
3.
Dev Biol Stand ; 35: 301-10, 1976.
Article in French | MEDLINE | ID: mdl-198300

ABSTRACT

The ponderal quantity of 140 S antigens and their peptide distribution are controlled in concentrated virulent and inactivated preparations proir to their being transformed into vaccines. A certain variability in the amount of 140 S particles and in the titer of peptide sensitive to trypsin (VP1) has been demonstrated in the virulent preparations. After treatment by inactivating agents (glycidaldehyde, binary ethyleneimine and formaldehyde) two types of alteration of the viral capsid are shown : one leads to the partial cleavage of VP1 (glycidaldehyde and binary ethyleneimine), the other leads to the detaching of an important quantity of VP1 from the capsid (formaldehyde). The degradation by formadehyde of the 140 S particles of type O and type C into 12 S particles is underlined, as well as the relatuve stability of type A and the relatuve lability of type C. The results are discussed in terms of immunogenicity.


Subject(s)
Antigens, Viral/analysis , Aphthovirus/immunology , Viral Vaccines/standards , Aphthovirus/drug effects , Aphthovirus/pathogenicity , Ethylenediamines/pharmacology , Formaldehyde/pharmacology , Glyceraldehyde/pharmacology , Peptides/analysis , Trypsin/pharmacology , Virulence
SELECTION OF CITATIONS
SEARCH DETAIL